Search

3rd Highlights of Past EHA (HOPE) in 2020 focused on Latin America a success!

November 13, 2020

Meeting Chairs:

Prof J Gribben (European Hematology Association)
Prof G Stemmelin (Argentinian Society of Hematology)

On November 13, EHA and the Argentinian Society of Hematology (SAH) kicked-off the second HOPE Latin America meeting in a virtual format.

Read more

EHA-SWG Scientific Meeting on MDS/MPN/AML: Commonalities and Differences of Myeloid Neoplasms

Join us for this unique and rare opportunity and exchange ideas with MDS, MPN, and AML experts in one meeting. Internationally renowned experts will provide presentations and share the recent developments and answers to your clinical questions.

Read more

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.

Read more

Gdf -11 a new target to improve anemia in thalassemia.

 

β-thalassemias are characterized by ineffective red blood cell (RBC) production, leading to anemia, iron overload, and organ failure. As current treatment options for β-thalassemia are limited, there is a clear unmet need for alternative therapies.

Read more

EHA Issues Recommendations on Mild to Moderate Bleeding Disorders

HemaSphere presents first in a series of Consensus Reports on Diagnosis of Inherited Bleeding Problems

For hematologists, it can be challenging to make the correct diagnosis in patients with bleeding problems – or even to determine whether there is any bleeding…

Read more

“Complement-ing” positive outcomes during the COVID-19 pandemic

Dr Dimitrios Mastellos (@dmastellos)

The COVID-19 pandemic has had a huge impact on research worldwide. Multiple projects have been halted and researchers have lost their jobs.

Read more

Dutch scientists propose algorithm to keep drugs affordable and accessible

May 8, 2018, The Hague - An important contribution to the debate about the affordability and accessibility of innovative medicines appeared in Nature Reviews, proposing the adoption of a novel model of price setting with examples of implementation.

Read more